Rimonabant, the first selective CB (1) receptor antagonist in clinical use, has been extensively investigated in the Rimonabant in Obesity (RIO) programme, comprising Rimonabant 20 mg daily consistentl reduced body weight, waist circumference, triglycerides, blood pressure, insulin resistance and creative protein levells, and increased HDL cholesterol concentrations in both non-diabetic overweight/obese patients. Adiponectin levels were increased, an effect that correlated wity HDL cholesterol augmentation, while small dense LDL c
No comments:
Post a Comment